Yorkshire Cancer Research   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Harrogate United Kingdom (1925)

Organization Overview

First Clinical Trial
2017
NCT03750110
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Yorkshire Cancer Research

Active Ingredients

Drugs in Phase 3 Trials (1)

icosapent ethyl (vascepa) (1 trial)

Drugs in Phase 2 Trials (2)

reolysin (1 trial)

sargramostim (leukine) (1 trial)

Drugs in Other Trials (3)

arginine (1 trial)

vitamin c (1 trial)

zinc sulfate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Neoplasms (Phase 3)

Liver Neoplasms (Phase 3)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Skin Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6